๐ฐ Colon News
Page 44 - Colon News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Colon. Real-time updates on events, politics, business and more.
November 1, 2023
Science Central’s annual fundraiser celebrating the craft of cocktails is Friday with six of the citys top bartenders competing. Also in The Dish: Acme By Full Circle to appear on
October 31, 2023
Colorectal cancer screening is widely recommended for adults ages 45 to 75 with an average risk of developing the disease. However, many people don't realize that the benefits of screening for this type of cancer aren't always the same for older adults.
October 30, 2023
It was the โaddiction memoirโ that laid things bare. Last year, when Matthew Perry released Friends, Lovers and the Big Terrible Thing , it detailed his...
October 30, 2023
Marmar Moussa, Ph.D., an assistant professor of computer science professor at the University of Oklahoma, has secured a nearly $1 million award from the National Institutes of Health to advance her work in computational genomics.
October 30, 2023
For too long, cancer treatment has been a double-edged sword โ the very treatments designed to kill cancer cells often wrought havoc on healthy ones too.
October 27, 2023
A meta-analysis published in Frontiers in Nutrition finds no link between moderate wine consumption and increased cancer risk; instead, it suggests that wine may have protective effects against certain types of tumors. Further research is needed to confirm these findings and understand the mechanisms involved.
October 27, 2023
With the question of Ohio legalizing recreational adult use of marijuana on the ballot Nov. 7, those in the medical cannabis industry are preparing for more growth.
October 27, 2023
Hudson girls soccer was left frustrated after its district final as Solon took advantage of its scoring chances, while the Explorers struggled.
October 26, 2023
Solon Mayor Eddy Kraus recently shared a statement in support of Israel at the city’s Oct. 16 council meeting.
October 23, 2023
A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.